IBSRELA 50 MG — DIN 02498049
TENAPANOR (TENAPANOR HYDROCHLORIDE) : 50 MG · KNIGHT THERAPEUTICS INC. · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is IBSRELA?
IBSRELA 50 MG contains TENAPANOR (TENAPANOR HYDROCHLORIDE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02498049, held by KNIGHT THERAPEUTICS INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-Jun-2026. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is IBSRELA used for?
IBSRELA® (tenapanor) is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Tablets: 50 mg tenapanor supplied as an oval, white to off-white film-coated, biconvex tablet, debossed with "450" on one side and "5791" on the other side. The tablets are packaged in a 75 mL high-density polyethylene (HDPE) bottle, with silica gel desiccant, induction sealed, and capped with a polypropylene child-resistant closure. Each bottle contains 60 tablets. |
| Storage | Store at room temperature (15 to 30°C). Keep IBSRELA tablets in the original container. Protect from moisture. Do not remove desiccant from the container. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Tenapanor |
|---|---|
| ATC code | A06AX08 |
| AHFS class | 40:18.19 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02498049 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2498049 |
| Brand name | IBSRELA |
| Generic / active ingredient | TENAPANOR (TENAPANOR HYDROCHLORIDE) : 50 MG |
| Market authorization holder | KNIGHT THERAPEUTICS INC. |
| Health Canada schedule | Prescription |
| ATC code | A06AX08 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A06AX |
| Current status | CANCELLED POST MARKET |
| Status date | 10-Jun-2026 |
| Original market date | 2020-11-23 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The recommended dosage in adults is 50 mg, oral twice daily. Take IBSRELA immediately prior to breakfast or the first meal of the day and immediately prior to dinner. Swallow IBSRELA tablets whole and do not crush or chew. In the event that a dose is missed, the patient should skip that dose. Do not take two tablets to account for the missed dose. Wait until it is time for the next dose and then take the usual dose. No dosage adjustment is required for patients with an eGFR >30 ml/min/1.73m². Patients with creatinine above 176 µmol/L (eGFR <30 ml/min/1.73m²) were excluded from pivotal studies. Monitor blood pressure and increase the dosage of enalapril (an OATP2B1 substrate), if needed, when IBSRELA is co-administered with enalapril.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Tenapanor is contraindicated in: • Pediatric patients under 6 years of age due to the risk of serious dehydration. • Patients who are hypersensitive to tenapanor or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. • Patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and precautions
Serious Warnings and Precautions: • Tenapanor is contraindicated in patients less than 6 years of age. • The use of Tenapanor in patients between 6 years and 18 years of age is not recommended. Risk of Serious Dehydration in Pediatric Patients: IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age has not been established. In young juvenile rats, tenapanor resulted in decreased body weight and mortality due to dehydration. The use of IBSRELA in patients 6 years to less than 18 years of age is not recommended. Gastrointestinal: Diarrhea was the most common adverse reaction. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient. Hepatic Impairment: The safety and efficacy of IBSRELA in IBS patients with hepatic dysfunction (ALT or AST > 2.5 times the upper limit of normal) has not been established. Renal Impairment: Safety and efficacy in patients with IBS-C and a creatinine above 176 µmol/L (eGFR <30 ml/min/1.73m²) have not been established. Diarrhea, including severe diarrhea, is more common in those with renal impairment than in those with normal renal function. Serious adverse reactions of hyperkalemia were reported in patients with chronic kidney disease and Type 2 diabetes mellitus treated with IBSRELA in a clinical trial for an unapproved indication.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC A06AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Prucalopride | APO-PRUCALOPRIDE · JAMP PRUCALOPRIDE · NRA-PRUCALOPRIDE · PMS-PRUCALOPRIDE · +2 more | 12 | 10 | Yes |
| Linaclotide | CONSTELLA | 3 | 3 | Yes |
| Plecanatide | TRULANCE | 1 | 1 | Yes |
| Glycerol | GLY-RECTAL SUP POUR ADULTES · GLYCERIN LIQ · GLYCERIN LIQUID · GLYCERIN SUPPOSITORIES · +7 more | 11 | 0 | Not in Canada |
| Other Laxatives | DYCHOLIUM TABLET 300MG | 1 | 0 | Not in Canada |
| Lubiprostone | AMITIZA | 1 | 0 | Not in Canada |
| Tenapanor | IBSRELA | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A06AB | Bisacodyl · Bisacodyl, Combinations · Cascara · Cascara, Combinations · Castor Oil · +9 more | 239 | 25 |
| A06AA | Docusate Sodium · Docusate Sodium, Combinations · Liquid Paraffin · Liquid Paraffin, Combinations | 144 | 22 |
| A06AD | Lactulose · Macrogol · Macrogol, Combinations · Magnesium Oxide · Magnesium Sulphate · +5 more | 86 | 21 |
| A06AH | Methylnaltrexone Bromide · Naloxegol | 5 | 3 |
| A06AG | Bisacodyl · Combinations · Docusate Sodium, Incl Combinations · Sodium Phosphate | 7 | 1 |
| A06AC | Ispaghula (Psylla Seeds) · Ispaghula, Combinations · Linseed · Methylcellulose · Polycarbophil Calcium · +2 more | 79 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is IBSRELA called?
Also recorded in Canada as: XPHOZAH (US), TENAPANOR (GLOBAL), TENAPANOR HYDROCHLORIDE (GLOBAL).
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.